Clinical Trials

 

Clinical Trials

Sutro is currently advancing two wholly owned clinical-stage programs designed to provide patient benefit across multiple areas of unmet need. 

 

STRO-001

ClinicalTrials.gov Identifier: NCT03424603
An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies.
STRO–001-BM1 has received Orphan Drug designation for Multiple Myeloma patients.
Status: Recruiting

 

STRO-002

ClinicalTrials.gov Identifier: NCT03748186
An Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers.
STRO-002-GM1 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids.
Status: Recruiting

 

BN301

ClinicalTrials.gov Identifier: NCT05611853
an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Status: Not Yet Recruiting

 

Sutro Biopharma’s investigational products have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. The safety and efficacy of investigational products have not been established.